269 related articles for article (PubMed ID: 27615383)
1. Established and emerging targeted therapies in the myelodysplastic syndromes.
Canaani J; Nagler A
Expert Rev Hematol; 2016 Oct; 9(10):997-1005. PubMed ID: 27615383
[TBL] [Abstract][Full Text] [Related]
2. Outlook and Management of Patients with Myelodysplastic Syndromes Failed by Hypomethylating Agents.
Roberts DA; Steensma DP
Curr Hematol Malig Rep; 2015 Sep; 10(3):318-28. PubMed ID: 26126600
[TBL] [Abstract][Full Text] [Related]
3. Epigenetic regulation in myelodysplastic syndromes: implications for therapy.
Vigna E; Recchia AG; Madeo A; Gentile M; Bossio S; Mazzone C; Lucia E; Morabito L; Gigliotti V; Stefano LD; Caruso N; Servillo P; Franzese S; Fimognari F; Bisconte MG; Gentile C; Morabito F
Expert Opin Investig Drugs; 2011 Apr; 20(4):465-93. PubMed ID: 21381982
[TBL] [Abstract][Full Text] [Related]
4. Management of lower-risk myelodysplastic syndromes without del5q: current approach and future trends.
Stahl M; Zeidan AM
Expert Rev Hematol; 2017 Apr; 10(4):345-364. PubMed ID: 28277851
[TBL] [Abstract][Full Text] [Related]
5. Treatment sequence of lenalidomide and hypomethylating agents and the impact on clinical outcomes for patients with myelodysplastic syndromes.
Zeidan AM; Klink AJ; McGuire M; Feinberg B
Leuk Lymphoma; 2019 Aug; 60(8):2050-2055. PubMed ID: 30636526
[TBL] [Abstract][Full Text] [Related]
6. Optimizing hypomethylating agents in myelodysplastic syndromes.
Itzykson R; Fenaux P
Curr Opin Hematol; 2012 Mar; 19(2):65-70. PubMed ID: 22248878
[TBL] [Abstract][Full Text] [Related]
7. The safety and efficacy of rigosertib in the treatment of myelodysplastic syndromes.
Navada SC; Silverman LR
Expert Rev Anticancer Ther; 2016 Aug; 16(8):805-10. PubMed ID: 27400247
[TBL] [Abstract][Full Text] [Related]
8. Hypomethylating agent combination strategies in myelodysplastic syndromes: hopes and shortcomings.
Ball B; Zeidan A; Gore SD; Prebet T
Leuk Lymphoma; 2017 May; 58(5):1022-1036. PubMed ID: 27654579
[TBL] [Abstract][Full Text] [Related]
9. Emerging biological therapies for the treatment of myelodysplastic syndromes.
Zeidan AM; Stahl M; Komrokji R
Expert Opin Emerg Drugs; 2016 Sep; 21(3):283-300. PubMed ID: 27486848
[TBL] [Abstract][Full Text] [Related]
10. The role of hypomethylating agents in myelodysplastic syndrome: changing the management paradigm.
Merkel DG; Nagler A
Expert Rev Hematol; 2013 Dec; 6(6):665-76. PubMed ID: 24191866
[TBL] [Abstract][Full Text] [Related]
11. Update on the pharmacotherapy for myelodysplastic syndromes.
Duong VH; Komrokji RS; List AF
Expert Opin Pharmacother; 2014 Sep; 15(13):1811-25. PubMed ID: 25080144
[TBL] [Abstract][Full Text] [Related]
12. Epigenetics in clinical practice: the examples of azacitidine and decitabine in myelodysplasia and acute myeloid leukemia.
Estey EH
Leukemia; 2013 Sep; 27(9):1803-12. PubMed ID: 23757301
[TBL] [Abstract][Full Text] [Related]
13. Digging deep into "dirty" drugs - modulation of the methylation machinery.
Pleyer L; Greil R
Drug Metab Rev; 2015 May; 47(2):252-79. PubMed ID: 25566693
[TBL] [Abstract][Full Text] [Related]
14. Hypomethylating agents in combination with immune checkpoint inhibitors in acute myeloid leukemia and myelodysplastic syndromes.
Daver N; Boddu P; Garcia-Manero G; Yadav SS; Sharma P; Allison J; Kantarjian H
Leukemia; 2018 May; 32(5):1094-1105. PubMed ID: 29487386
[TBL] [Abstract][Full Text] [Related]
15. Management of higher risk myelodysplastic syndromes after hypomethylating agents failure: are we about to exit the black hole?
Bewersdorf JP; Zeidan AM
Expert Rev Hematol; 2020 Oct; 13(10):1131-1142. PubMed ID: 32876498
[TBL] [Abstract][Full Text] [Related]
16. The euphoria of hypomethylating agents in MDS and AML: is it justified?
Sekeres MA
Best Pract Res Clin Haematol; 2013 Sep; 26(3):275-8. PubMed ID: 24309530
[TBL] [Abstract][Full Text] [Related]
17. Clinical results with the DNA hypomethylating agent 5-aza-2'-deoxycytidine (decitabine) in patients with myelodysplastic syndromes: an update.
Joeckel TE; Lübbert M
Semin Hematol; 2012 Oct; 49(4):330-41. PubMed ID: 23079063
[TBL] [Abstract][Full Text] [Related]
18. DNA methylation profiling of myelodysplastic syndromes and clinical response to azacitidine: A multicentre retrospective study.
Noguera-Castells A; Campillo-Marcos I; Davalos V; García-Prieto CA; Valcárcel D; Molero A; Palomo L; Gattermann N; Wulfert M; Chaparro-González L; Solé F; Cabezón M; Jiménez-Lorenzo MJ; Xicoy B; Zamora L; De Stefano A; Casalin I; Finelli C; Follo MY; Esteller M
Br J Haematol; 2024 May; 204(5):1838-1843. PubMed ID: 38471524
[TBL] [Abstract][Full Text] [Related]
19. New therapeutic approaches in myelodysplastic syndromes: Hypomethylating agents and lenalidomide.
Loiseau C; Ali A; Itzykson R
Exp Hematol; 2015 Aug; 43(8):661-72. PubMed ID: 26123365
[TBL] [Abstract][Full Text] [Related]
20. Immunological effects of hypomethylating agents.
Lindblad KE; Goswami M; Hourigan CS; Oetjen KA
Expert Rev Hematol; 2017 Aug; 10(8):745-752. PubMed ID: 28644756
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
